Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects

Reuters

Aug 28, 2025

Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href="https://laohu8.com/S/CCOOF">Core Assets</a> to Boost U.S. Listing Prospects

Argent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562544773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562544773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562544773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562544773","market":"us","top_or_hot":-1,"title":"Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href=\"https://laohu8.com/S/CCOOF\">Core Assets</a> to Boost U.S. Listing Prospects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MGCLF\">Argent BioPharma</a> Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's <a href=\"https://laohu8.com/S/CCOOF\">Core Assets</a> to Boost U.S. Listing Prospects\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MGCLF\">Argent BioPharma</a> Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL7qR0GW:1","article_id":"2562544773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562544773","pubTimestamp":1756330244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Argent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil and CimetrA, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","RGT.AU":"Argent BioPharma Limited"},"translate_title":"Argent Biopharma Ltd.宣布战略收购AusCann核心资产提振美国上市前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGT.AU":0.9},"content_text":"Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects\n    \n\nArgent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis® patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil® and CimetrA®, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60454) on August 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}